• Raymond James reaffirmed a "Strong Buy" rating for Ardelyx, Inc. (NASDAQ:ARDX), raising the price target from $16 to $19.
• The average price target set by Wall Street analysts suggests a potential upside of 92.1% for ARDX.
• ARDX stock has seen a significant increase of 19.98%, with today's trading volume reaching 10,385,198 shares on the NASDAQ exchange.

Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company focused on developing innovative treatments for unmet medical needs. On January 8, 2026, Raymond James reaffirmed its "Strong Buy" rating for ARDX, maintaining its previous grade. At the time of this announcement, the stock was trading at $6.95. Raymond James also raised the price target for Ardelyx from $16 to $19.

Wall Street analysts have set an average price target for ARDX that suggests a potential upside of 92.1%. Despite some skepticism about the reliability of this metric, the positive trend in earnings estimate revisions could lead to an increase in the stock's value. Over the past four weeks, Ardelyx shares have risen by 3.6%, closing the last trading session at $6.09.

Analysts' short-term price targets for Ardelyx range from $8.00 to $16.00, with a mean estimate of $11.7. This range indicates a potential increase of 31.4% to 162.7% from the current price level. The standard deviation of $2.71 among these estimates highlights the variability and agreement among analysts.

The stock for ARDX is currently priced at $6.99, reflecting a significant increase of 19.98% with a change of $1.16. Today, the stock has fluctuated between a low of $6.12 and a high of $7.02, which also marks its highest price over the past year. The lowest price for the stock in the past year was $3.21.

ARDX has a market capitalization of approximately $1.68 billion. The trading volume for the stock today is 10,385,198 shares on the NASDAQ exchange. While the consensus price target is a popular tool for investors, the accuracy and impartiality of analysts in setting these targets remain a topic of discussion.